378 related articles for article (PubMed ID: 34333002)
1. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes.
Yun JS; Ko SH
Metabolism; 2021 Oct; 123():154838. PubMed ID: 34333002
[TBL] [Abstract][Full Text] [Related]
2. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
3. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus-Part 1.
Yandrapalli S; Jolly G; Horblitt A; Pemmasani G; Sanaani A; Aronow WS; Frishman WH
Cardiol Rev; 2020; 28(4):177-189. PubMed ID: 32282393
[TBL] [Abstract][Full Text] [Related]
5. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice.
Patoulias D; Stavropoulos K; Imprialos K; Athyros V; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2020; 18(2):125-138. PubMed ID: 32013815
[TBL] [Abstract][Full Text] [Related]
8. The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes.
Dey AK; Groenendyk J; Mehta NN; Gourgari E
Clin Cardiol; 2019 Mar; 42(3):406-412. PubMed ID: 30635924
[TBL] [Abstract][Full Text] [Related]
9. HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity.
Mohanan PP; Jariwala P
Indian Heart J; 2023; 75(1):1-8. PubMed ID: 36435205
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
11. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
Urquhart S; Willis S
JAAPA; 2020 Aug; 33(S8 Suppl 1):19-30. PubMed ID: 32756221
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients.
Uneda K; Kawai Y; Yamada T; Kinguchi S; Azushima K; Kanaoka T; Toya Y; Wakui H; Tamura K
Sci Rep; 2021 May; 11(1):10166. PubMed ID: 33986377
[TBL] [Abstract][Full Text] [Related]
13. Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology.
Hong T; Su Q; Li X; Shan Z; Chen L; Peng Y; Chen L; Yan L; Bao Y; Lyu Z; Shi L; Wang W; Guo L; Ning G; Mu Y; Zhu D
Diabetes Metab Res Rev; 2021 May; 37(4):e3416. PubMed ID: 33120435
[TBL] [Abstract][Full Text] [Related]
14. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
Urquhart S; Willis S
JAAPA; 2020 Aug; 33(8):19-30. PubMed ID: 32740122
[TBL] [Abstract][Full Text] [Related]
15. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
Dailey G
Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular disease prevention strategies for type 2 diabetes mellitus.
Katsiki N; Purrello F; Tsioufis C; Mikhailidis DP
Expert Opin Pharmacother; 2017 Aug; 18(12):1243-1260. PubMed ID: 28685623
[TBL] [Abstract][Full Text] [Related]
17. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.
Sposito AC; Berwanger O; de Carvalho LSF; Saraiva JFK
Cardiovasc Diabetol; 2018 Dec; 17(1):157. PubMed ID: 30545359
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2.
Yandrapalli S; Malik A; Horblitt A; Pemmasani G; Aronow WS; Frishman WH
Cardiol Rev; 2020; 28(5):219-235. PubMed ID: 32271194
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
[TBL] [Abstract][Full Text] [Related]
20. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
Hupfeld C; Mudaliar S
Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
